What is the significance of MUM1 (Multiple Myeloma 1) in Burkitt lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

MUM1 is typically negative in Burkitt lymphoma, which is a crucial diagnostic feature that distinguishes it from other aggressive B-cell lymphomas. When evaluating a suspected case of Burkitt lymphoma, immunohistochemical staining for MUM1 should be performed as part of a comprehensive panel, including CD10, BCL6, and Ki-67, to establish the correct diagnosis 1. The absence of MUM1 in Burkitt lymphoma, combined with other markers (CD20+, CD10+, BCL6+, BCL2-, Ki-67 nearly 100%) and the presence of MYC rearrangement, helps confirm the diagnosis. Accurate diagnosis is crucial as Burkitt lymphoma requires specific intensive chemotherapy regimens, such as those including rituximab, which has been shown to improve outcomes in adult Burkitt lymphoma/leukaemia 1. Some key points to consider when evaluating Burkitt lymphoma include:

  • The importance of MUM1 negativity in the diagnosis of Burkitt lymphoma
  • The use of immunohistochemical staining for MUM1, CD10, BCL6, and Ki-67 to establish the correct diagnosis
  • The distinction between Burkitt lymphoma and other aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL), which often express MUM1
  • The need for accurate diagnosis to guide treatment decisions, including the use of intensive chemotherapy regimens and targeted therapies like rituximab.

From the Research

Mum1 in Burkitt Lymphoma

  • There is no direct information available on Mum1 in Burkitt lymphoma from the provided studies 2, 3, 4, 5, 6.
  • However, the studies discuss the treatment and management of Burkitt lymphoma, including the use of intensive chemotherapy regimens and rituximab 2, 3, 5, 6.
  • The studies also highlight the importance of prompt diagnosis and initiation of appropriate therapy to achieve optimal results 4, 5.
  • Some of the studies mention the use of specific chemotherapy regimens, such as CODOX-M/IVAC and DA-EPOCH-R, which have shown high cure rates in patients with Burkitt lymphoma 2, 5, 6.
  • The role of Mum1 in Burkitt lymphoma is not explicitly discussed in the provided studies, suggesting that there may be a need for further research on this topic.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.